Brief Title
Bridging Study for Killed Oral Cholera Vaccine in Ethiopia
Official Title
A Randomized, Double-blind, Controlled Trial to Evaluate the Safety and Immunogenicity of Killed Bivalent (o1 and o139) Whole-cell Based Oral Cholera Vaccine (Shanchol®) in Healthy Individuals in Ethiopia
Brief Summary
This is a randomized, double blind, placebo controlled trial to confirm the safety and determine the immune response of the killed oral cholera vaccine in healthy adults and children in Ethiopia.
Detailed Description
This study serves as a bridging trial to evaluate the safety and immunogenicity of a two dose regimen of the WC-OCV (Shanchol®) in Ethiopian population. In order to assess whether the bivalent killed oral cholera vaccine may be used safely among those who are most at risk for cholera, we need to determine the safety and immunogenicity of the killed oral cholera vaccine. The vaccine was evaluated in a large number of human subjects in India Vietnam, and Bangladesh, in which it has demonstrated safety, immunogenicity, and clinical protective efficacy. Though we do not expect the vaccine to act differently in the Ethiopian population, we aim to confirm our presumptive understanding that two doses of WC-OCV is safe and immunogenic in healthy volunteers at one year and above (exclusive of pregnant women). Findings from this study can pave the way for the possible use of the killed whole cell oral cholera vaccine in both endemic and outbreak settings at a larger scale.
Study Phase
Phase 4
Study Type
Interventional
Primary Outcome
Proportion of subjects given investigational product with adverse events.
Secondary Outcome
Proportion of subjects exhibiting 4-fold or greater rises in titers of serum vibriocidal antibodies, relative to baseline, 14 days after the first dose.
Condition
Vibrio Cholerae
Intervention
Killed Bivalent (O1 and O139) whole cell oral cholera vaccine
Study Arms / Comparison Groups
Killed oral cholera vaccine
Description: Killed Bivalent (O1 and O139) Whole cell oral cholera vaccine (Shanchol TM) Vaccine strain Reformulated version V. cholerae O1 Inaba El Tor strain Phil 6973 formalin killed 600 Elisa units (EU) of lipopolysaccharide (LPS) V. cholerae O1 Ogawa classical strain Cairo 50 heat killed 300 EU LPS V. cholerae O1 Ogawa classical strain Cairo 50 formalin killed 300 EU LPS V. cholerae O1 Inaba classical strain Cairo 48 heat killed 300 EU LPS V. cholerae O139 strain 4260B formalin killed 600 EU LPS
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Biological
Estimated Enrollment
216
Start Date
December 2012
Completion Date
August 2013
Primary Completion Date
August 2013
Eligibility Criteria
Inclusion Criteria: 1. Male or female adults aged 18 years and above; and children aged 1 -17 years who is available for follow-up visits and specimen collection. - The subject should be able to continue in the study for the next 4 weeks - The subject (or parent/guardian) should be willing to provide 3 blood samples 2. For females of reproductive age, non-pregnant (as determined by urine pregnancy test). 3. Written informed consent obtained from the subjects or their parents/guardians, and written assent obtained from children aged 12 - 17 years. 4. Healthy subjects as determined by: - Medical history - Physical examination - Clinical judgment of the investigator Exclusion Criteria: 1. Ongoing chronic recurring illness which may cause systemic symptoms as judged by the investigating physician. 2. Ongoing acute illness. 3. For females of reproductive age: Pregnancy (or females planning to become pregnant during the study period; as determined by verbal screening) 4. Immunocompromising condition or on chronic systemic steroid therapy 5. Diarrhea (3 or more loose/more watery stools within a 24-hour period) within 6 weeks prior to enrollment 6. Intake of any anti-diarrhea medicine in the past week 7. Abdominal pain or cramps, loss of appetite, nausea, or vomiting in the past 24 hours 8. Temperature ≥38ºC (oral or axillary) warrants deferral of the vaccination pending recovery of the subject 9. Previous hypersensitivity to formaldehyde. 10. Receipt of immunoglobulin or any blood product during the past 3 months 11. Receipt of oral cholera vaccine in the past three years 12. Any potential subject currently participating or who will participate within the next six months in another clinical trial 13. Positive screening urine pregnancy test for females greater than 12 years of age
Gender
All
Ages
1 Year - N/A
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Contacts
, ,
Location Countries
Ethiopia
Location Countries
Ethiopia
Administrative Informations
NCT ID
NCT01524640
Organization ID
CR-WC-09
Responsible Party
Sponsor
Study Sponsor
International Vaccine Institute
Collaborators
Armauer Hansen Research Institute, Ethiopia
Study Sponsor
, ,
Verification Date
May 2015